2Birgir Gudjonsson. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. Am Coll Surg, 1995, 181:483-503.
3Adsay NV, Conlon KC, Zee SY, et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer, 2002, 94:62-77.
4Bluemke DA, Cameron JL, Hruban RH. Potentially respectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology, 1995, 197:381-385.
5Banfi G, Zerbi A, Pastori S, et al. Behavior of tumor markers. CA19-9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem, 1993, 39: 420-423.
6Tian F, Appert HE, Myles J, et al. Prognostic value of serum CA19-9 levels in pancreatic adenocarcinoma. Ann Surg, 1992, 215: 350-355.
7Paulino AC, Latona C. Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. Cancer Invest, 2000, 18: 309-313.
8Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas- 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg, 2000, 4: 567-579.
